Milsom Chloe, Magnus Nathalie, Meehan Brian, Al-Nedawi Khalid, Garnier Delphine, Rak Janusz
Montreal Children's Hospital, McGill University, QC, Canada.
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2005-14. doi: 10.1161/ATVBAHA.108.177444. Epub 2009 Jul 23.
A common feature in the progression of multiple human malignancies is the protracted deregulation of the coagulation system, often referred to as cancer coagulopathy. Indeed, cancer cells and their vascular stroma often exhibit procoagulant properties, of which deregulation of tissue factor (TF) expression is a notable, although not the sole example. These changes can be traced to oncogenic influences affecting epidermal growth factor receptor (EGFR), EGFRvIII, K-ras, p53, PTEN, and probably many other proto-oncogenes and tumor suppressors in tumor parenchyma. Cancer stem cells (CSCs)/tumor initiating cells (TICs) are thought to represent the primary target and the main cellular effector through which oncogenic mutations exert their tumor-inducing effects. In so doing, CSCs/TICs depend on interactions with the tumor vasculature, which forms supportive niches for their clonal growth. We postulate that TF contributes to these interactions (directly or indirectly) through procoagulant and signaling effects, the latter executed in concert with juxtaposed protease activated receptors (mainly PAR-1 and PAR-2). TF/PAR system acts as a "blood sensing" mechanism, whereby cancer cells, including CSCs/TICs, may respond to plasma proteases (Factors VIIa, Xa, and IIa) and their related microenvironmental changes (fibrin deposition, activation of platelets). A growing body of still largely circumstantial evidence suggests that these events may contribute to the CSC/TIC niche, which could influence tumor initiation, metastasis, recurrence, and therapeutic intractability. Indeed, certain types of cancer cells harboring markers of CSCs (CD133) exhibit elevated TF expression and depend on this receptor to efficiently initiate tumor growth. We propose that both tumor cell-associated and host-related TF could influence the properties of CSCs, and that agents targeting the TF/PAR system may represent a hitherto unappreciated therapeutic opportunity to control cancer progression by influencing the CSC/TIC compartment.
多种人类恶性肿瘤进展过程中的一个共同特征是凝血系统长期失调,通常称为癌症凝血病。事实上,癌细胞及其血管基质通常表现出促凝特性,其中组织因子(TF)表达失调是一个显著的例子,尽管不是唯一的例子。这些变化可追溯到影响肿瘤实质中表皮生长因子受体(EGFR)、EGFRvIII、K-ras、p53、PTEN以及可能许多其他原癌基因和肿瘤抑制因子的致癌影响。癌症干细胞(CSCs)/肿瘤起始细胞(TICs)被认为是致癌突变发挥其肿瘤诱导作用的主要靶点和主要细胞效应器。在此过程中,CSCs/TICs依赖于与肿瘤脉管系统的相互作用,肿瘤脉管系统为它们的克隆生长形成支持性微环境。我们推测TF通过促凝和信号作用(后者与并列的蛋白酶激活受体(主要是PAR-1和PAR-2)协同执行)对这些相互作用(直接或间接)有贡献。TF/PAR系统作为一种“血液感知”机制,由此癌细胞,包括CSCs/TICs,可能对血浆蛋白酶(因子VIIa、Xa和IIa)及其相关的微环境变化(纤维蛋白沉积、血小板激活)作出反应。越来越多的、很大程度上仍为间接的证据表明这些事件可能有助于CSC/TIC微环境的形成,这可能影响肿瘤的起始、转移、复发和治疗难治性。事实上,某些带有CSCs标记(CD133)的癌细胞表现出TF表达升高,并依赖该受体有效地启动肿瘤生长。我们提出肿瘤细胞相关的和宿主相关的TF都可能影响CSCs的特性,并且靶向TF/PAR系统的药物可能代表了一个迄今未被重视的治疗机会,即通过影响CSC/TIC区室来控制癌症进展。